IRIS
FERRARO, Giuseppa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.276
NA - Nord America 2.535
AS - Asia 1.331
SA - Sud America 354
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 7.540
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.488
RU - Federazione Russa 1.755
SG - Singapore 535
CN - Cina 429
SE - Svezia 403
IE - Irlanda 353
BR - Brasile 307
DE - Germania 143
HK - Hong Kong 140
FR - Francia 129
IT - Italia 110
UA - Ucraina 101
PL - Polonia 71
FI - Finlandia 69
GB - Regno Unito 68
VN - Vietnam 61
IN - India 48
CA - Canada 21
AR - Argentina 19
BE - Belgio 18
AT - Austria 17
BD - Bangladesh 16
ZA - Sudafrica 16
ID - Indonesia 13
MX - Messico 13
TR - Turchia 13
CO - Colombia 12
IQ - Iraq 12
NL - Olanda 10
MA - Marocco 8
PK - Pakistan 8
SA - Arabia Saudita 8
JP - Giappone 7
PH - Filippine 6
AE - Emirati Arabi Uniti 5
JM - Giamaica 5
UZ - Uzbekistan 5
DZ - Algeria 4
EC - Ecuador 4
ES - Italia 4
ET - Etiopia 4
JO - Giordania 4
VE - Venezuela 4
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
LT - Lituania 3
LV - Lettonia 3
PE - Perù 3
RO - Romania 3
RS - Serbia 3
AL - Albania 2
AZ - Azerbaigian 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DK - Danimarca 2
IR - Iran 2
KE - Kenya 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TH - Thailandia 2
TN - Tunisia 2
AU - Australia 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
CL - Cile 1
EU - Europa 1
GR - Grecia 1
GY - Guiana 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.540
Salva come PNG Salva come JPEG
Città #
Moscow 461
Ashburn 375
Dublin 352
Singapore 319
Chandler 309
Dallas 241
Nyköping 205
Jacksonville 197
Beijing 158
Hong Kong 140
San Jose 92
The Dalles 87
New York 78
Warsaw 65
Ann Arbor 63
Los Angeles 61
Dearborn 58
Cambridge 51
Princeton 51
Medford 49
Lauterbourg 44
Des Moines 42
Messina 41
Munich 41
Boardman 34
Buffalo 30
Jinan 25
São Paulo 23
Woodbridge 22
Frankfurt am Main 21
Tianjin 21
Pune 19
Brussels 18
Ho Chi Minh City 18
San Mateo 17
Vienna 17
Lancaster 16
Shenyang 14
Turku 14
Belo Horizonte 13
Wilmington 13
Guangzhou 12
Redondo Beach 12
Nanjing 11
Orem 11
Brooklyn 10
Hebei 10
Johannesburg 10
Montreal 10
Zhengzhou 10
Chennai 9
Houston 9
Chicago 8
Council Bluffs 8
Hanoi 8
Manchester 8
Atlanta 7
Baghdad 7
Campinas 7
Dong Ket 7
London 7
Rio de Janeiro 7
San Francisco 7
Shenzhen 7
Amsterdam 6
Da Nang 6
Denver 6
Goiânia 6
Grammichele 6
Jakarta 6
Mexico City 6
Mumbai 6
Ningbo 6
Shanghai 6
Taizhou 6
Ankara 5
Augusta 5
Brasília 5
Changsha 5
Dhaka 5
Fort Washington 5
Helsinki 5
Joinville 5
Santa Clara 5
Stockholm 5
Tashkent 5
Tokyo 5
Washington 5
Addis Ababa 4
Boston 4
Curitiba 4
Fuzhou 4
Haikou 4
Hillsboro 4
Lanzhou 4
Leawood 4
Miami 4
Roubaix 4
Seattle 4
Amman 3
Totale 4.295
Salva come PNG Salva come JPEG
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 238
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 228
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 221
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 215
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 208
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 194
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 182
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 181
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 181
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 178
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 173
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 172
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 168
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 164
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 164
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 163
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 160
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 156
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 156
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 154
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 154
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 152
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 152
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 152
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 146
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 146
RANDOMISED PHASE II TERTIARY CHEMOPREVENTION TRIAL FOR COLORECTAL ADENOMA IN 24 PATIENTS WITH COLORECTAL CANCER TREATED WITH CELECOXIB 144
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 143
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 141
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 139
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 138
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 134
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient 132
NSCLC and HER2: between lights and shadows 131
Early Breast Cancer HER2 positivo in postmenopausa: strategia terapeutica adiuvante 130
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 128
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 127
Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity 125
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 122
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 116
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 112
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 110
Neoplasie della testa collo nell’ anziano 109
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 104
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 102
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 101
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 95
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 89
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 88
Invecchiamento e cancro. 84
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 59
null 52
null 37
null 33
null 22
Totale 7.605
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.790
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.790
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021118 0 0 0 0 0 0 0 0 0 39 53 26
2021/2022412 2 66 10 11 14 6 23 9 5 99 57 110
2022/20231.137 87 118 49 105 83 104 18 88 444 2 29 10
2023/2024313 18 50 15 27 16 124 30 17 0 4 1 11
2024/20251.030 8 9 19 68 47 42 12 181 268 60 98 218
2025/20263.483 181 197 243 186 289 804 469 514 487 113 0 0
Totale 7.605